Xiaofei Ye

Dec 29, 2023 | nature.com | Hui Wan |Xianhuo Wang |Dongbing Liu |Xiaofei Ye |Gunilla Enblad |Rose-Marie Amini | +3 more

AbstractDespite the improvements in clinical outcomes for DLBCL, a significant proportion of patients still face challenges with refractory/relapsed (R/R) disease after receiving first-line R-CHOP treatment. To further elucidate the underlying mechanism of R/R disease and to develop methods for identifying patients at risk of early disease progression, we integrated clinical, genetic and transcriptomic data derived from 2805 R-CHOP-treated patients from seven independent cohorts.

Mar 14, 2023 | mdpi.com | Yaxi Han |Tao Wang |Dong Shi |Xiaofei Ye

Open AccessArticlebyYaxi Han 1, Tao Wang 1,*, Dong Shi 1, Xiaofei Ye 2 and Quan Yuan 3 1Guangxi Key Laboratory of Intelligent Transportation System, Guilin University of Electronic Technology, Guilin 541004, China2Faculty of Maritime and Transportation, Ningbo University, Ningbo 315211, China3State Key Laboratory of Automotive Safety and Energy, School of Vehicle and Mobility, Tsinghua University, Beijing 100084, China*Author to whom correspondence should be addressed.